Michele Marchioni1,2,3,4, Marta Di Nicola1,2, Giulia Primiceri1,3,4, Giacomo Novara5, Pietro Castellan4, Asit K Paul6, Alessandro Veccia7, Riccardo Autorino7, Luca Cindolo8, Luigi Schips1,3,4. 1. Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University of Chieti, Chieti, Italy. 2. Laboratory of Biostatistics, G. d'Annunzio University of Chieti, Chieti, Italy. 3. Urology Unit, SS. Annunziata Hospital, Chieti, Italy. 4. Department of Urology, Azienda Sanitaria Locale Abruzzo, Chieti, Italy. 5. Department of Surgery, Oncology, and Gastroenterology-Urology Clinic, University of Padua, Padua, Italy. 6. Division of Hematology, Oncology and Palliative Care, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia. 7. Division of Urology, Virginia Commonwealth University Health, Richmond, Virginia. 8. Department of Urology, Villa Stuart Hospital, Rome, Italy.
Abstract
PURPOSE: Docetaxel represent the standard of care in patients with metastatic, hormone sensitive prostate cancer. However, androgen receptor axis targeted therapies have also been shown to be effective. We aimed to analyze findings in randomized controlled trials investigating first-line treatment for hormone sensitive prostate cancer. MATERIALS AND METHODS: We systematically reviewed the literature according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) criteria and the PICO (Population, Intervention, Comparator, Outcomes) methodology. Outcomes of interest were overall and progression-free survival, and the rate of high grade adverse events. RESULTS: No treatment was superior to docetaxel in terms of overall survival. However, abiraterone (HR 0.89, 95% CI 0.76-1.05), enzalutamide (HR 0.90, 95% CI 0.69-1.19) and apalutamide (HR 0.90, 95% CI 0.67-1.22) showed nonstatistically significant lower overall mortality rates than docetaxel. Abiraterone (HR 0.71, 95% CI 0.59-0.86), enzalutamide (HR 0.61, 95% CI 0.49-0.75) and apalutamide (HR 0.74, 95% CI 0.57-0.95) also showed statistically significant lower disease progression rates than docetaxel. Furthermore, abiraterone (OR 0.83, 95% CI 0.56-1.21) showed no statistically significant lower rate of high grade adverse events compared to docetaxel. Finally, enzalutamide (OR 0.56, 95% CI 0.35-0.92) and apalutamide (OR 0.44, 95% CI 0.24-0.79) showed statistically significant lower rates of high grade adverse events compared to docetaxel. CONCLUSIONS: Treatment with androgen receptor axis targeted therapies combined with androgen deprivation therapy in patients with hormone sensitive prostate cancer did not offer a statistically significant advantage in overall survival compared to the standard, docetaxel. However, it was associated with a lower disease progression rate. Moreover, apalutamide and enzalutamide offer a better safety profile.
PURPOSE:Docetaxel represent the standard of care in patients with metastatic, hormone sensitive prostate cancer. However, androgen receptor axis targeted therapies have also been shown to be effective. We aimed to analyze findings in randomized controlled trials investigating first-line treatment for hormone sensitive prostate cancer. MATERIALS AND METHODS: We systematically reviewed the literature according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) criteria and the PICO (Population, Intervention, Comparator, Outcomes) methodology. Outcomes of interest were overall and progression-free survival, and the rate of high grade adverse events. RESULTS: No treatment was superior to docetaxel in terms of overall survival. However, abiraterone (HR 0.89, 95% CI 0.76-1.05), enzalutamide (HR 0.90, 95% CI 0.69-1.19) and apalutamide (HR 0.90, 95% CI 0.67-1.22) showed nonstatistically significant lower overall mortality rates than docetaxel. Abiraterone (HR 0.71, 95% CI 0.59-0.86), enzalutamide (HR 0.61, 95% CI 0.49-0.75) and apalutamide (HR 0.74, 95% CI 0.57-0.95) also showed statistically significant lower disease progression rates than docetaxel. Furthermore, abiraterone (OR 0.83, 95% CI 0.56-1.21) showed no statistically significant lower rate of high grade adverse events compared to docetaxel. Finally, enzalutamide (OR 0.56, 95% CI 0.35-0.92) and apalutamide (OR 0.44, 95% CI 0.24-0.79) showed statistically significant lower rates of high grade adverse events compared to docetaxel. CONCLUSIONS: Treatment with androgen receptor axis targeted therapies combined with androgen deprivation therapy in patients with hormone sensitive prostate cancer did not offer a statistically significant advantage in overall survival compared to the standard, docetaxel. However, it was associated with a lower disease progression rate. Moreover, apalutamide and enzalutamide offer a better safety profile.
Entities:
Keywords:
androgen; drug related side effects and adverse reactions; mortality; neoplasm metastasis; prostatic neoplasms; receptors
Authors: Mary E Hall; Heather L Huelster; Amy N Luckenbaugh; Aaron A Laviana; Kirk A Keegan; Zachary Klaassen; Kelvin A Moses; Christopher J D Wallis Journal: Onco Targets Ther Date: 2020-04-29 Impact factor: 4.147
Authors: Martin John Connor; Mesfin G Genie; Michael Gonzalez; Naveed Sarwar; Kamalram Thippu Jayaprakash; Gail Horan; Feargus Hosking-Jervis; Natalia Klimowska-Nassar; Johanna Sukumar; Tzveta Pokrovska; Dolan Basak; Angus Robinson; Mark Beresford; Bhavan Rai; Stephen Mangar; Vincent Khoo; Tim Dudderidge; Alison Falconer; Mathias Winkler; Verity Watson; Hashim Uddin Ahmed Journal: BMJ Open Date: 2021-11-18 Impact factor: 2.692
Authors: A González Del Alba; M J Méndez-Vidal; S Vazquez; E Castro; M A Climent; E Gallardo; E Gonzalez-Billalabeitia; D Lorente; J P Maroto; J A Arranz Journal: Clin Transl Oncol Date: 2021-02-24 Impact factor: 3.405
Authors: Igor Tsaur; Isabel Heidegger; Jasmin Bektic; Mona Kafka; Roderick C N van den Bergh; Jarmo C B Hunting; Anita Thomas; Maximilian P Brandt; Thomas Höfner; Eliott Debedde; Constance Thibault; Paola Ermacora; Fabio Zattoni; Silvia Foti; Alexander Kretschmer; Guillaume Ploussard; Severin Rodler; Gunhild von Amsberg; Derya Tilki; Christian Surcel; Barak Rosenzweig; Moran Gadot; Giorgio Gandaglia; Robert Dotzauer Journal: Cancer Med Date: 2021-08-10 Impact factor: 4.452
Authors: Keiichiro Mori; Hadi Mostafaei; Reza Sari Motlagh; Benjamin Pradere; Fahad Quhal; Ekaterina Laukhtina; Victor M Schuettfort; Gero Kramer; Mohammad Abufaraj; Pierre I Karakiewicz; Takahiro Kimura; Shin Egawa; Shahrokh F Shariat Journal: BJU Int Date: 2021-07-21 Impact factor: 5.969